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the positive response ratio was calculated by dividing the number of patients who fol-
lowed the pharmacist advice to total number of patients to whom the advice was pro-
vided. The cost saving per patient per year was determined from available literature. 
RESULTS: A total of 180 interventions were made by the pharmacists. Pattern manage-
ment (100 cases, 55.5%) and alerting physician of an abnormal A1c (61, 33.8%) were
the most frequent. The most accepted interventions were glucometer training (2 cases, 
100%), advising to correct hypoglycemic/hyperglycemic episodes (12, 66.7%), and 
instructing on the proper use of their injectables (5, 60.0%). Cost savings of $1914/
patient/year were estimated as a result of the 4th and 5th intervention. Also, interven-
tions 1, 2 and 3 resulted in cost-saving of $1161, $ 1203, and $1531 per patient per 
year respectively. CONCLUSIONS: Our model showed that pharmacist interventions 
can result in signiﬁ cant cost savings among diabetic patients.
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OBJECTIVES: To evaluate the impact of a specialty care management program (Pre-
cisionRx Pharmacy Management) on medication adherence, risk of hospitalization, 
and costs of care among MS patients. METHODS: This study was a retrospective 
analysis of administrative claims from 13 geographically dispersed US commercial
health plans. Patients aged 18–64 years with q2 claims of MS diagnosis and q1 MS
medications (Interferon beta-1a, Interferon beta-1b, and Glatiramer acetate) from
January 1, 2004 and April 30, 2008 were identiﬁ ed. For patients enrolled in Preci-
sionRx program (managed), index date was deﬁ ned as the program participation date; 
for other patients (non-managed), index date was randomly assigned through Monte
Carlo simulation with regard to the managed patients. At least 12 months of continu-
ous eligibility pre- and post- index was required. Outcome metrics included medication 
adherence (measured by medication possession ratio (MPR)), risk of MS-related
hospitalization, and MS-related costs. Multivariate analyses were performed to adjust
for baseline demographics, baseline health care costs, and clinical characteristics. 
RESULTS: Among 3862 patients identiﬁ ed, 79% were managed and 21% were non-
managed patients. The multivariate analysis showed that compared with the non-
managed group, the managed group had 0.21 higher MPR (95% CI: 0.19–0.23, p 
0.001), were less likely to be hospitalized for MS (adjusted odds ratio: 0.53 (0.40–
0.70), p  0.001), and had 25% higher MS-related costs (95% CI: 20%-31%, p 
0.001), controlling for other covariates. The relatively larger increase in MS-related 
costs from pre-index to post-index among the managed group (median: $3791 vs. 
$2277) was primarily driven by larger increase in their pharmacy costs (median: $3968 
vs. $1885). CONCLUSIONS: Overall, this specialty care management program was 
associated with better medication adherence and lower risk of MS-related hospitaliza-
tion. The associated higher MS-related costs among the managed group could be
explained by their relatively larger increase in pharmacy costs, as expected due to
better medication adherence and high costs of MS medication.
HM4
THE IMPACT OF A PHARMACIST–PROVIDED TELEPHONE MEDICATION
THERAPY MANAGEMENT PROGRAM ON MEDICATION AND HEALTH–
RELATED PROBLEMS, MEDICATION ADHERENCE, AND TOTAL DRUG
COSTS AMONG MEDICARE BENEFICIARIES: A 6–MONTH FOLLOW–UP
Moczygemba LR1, Barner JC2, Lawson KA2, Brown CM2, Gabrillo E3, Godley PJ4, 
Johnsrud M2
1Virginia Commonwealth University, Richmond, VA, USA, 2University of  Texas at Austin, 
Austin, TX, USA, 3Scott and White Health Plan, Temple, TX, USA, 4Scott and White Health 
System, Temple, TX, USA
OBJECTIVES: To determine if differences existed between the intervention group 
[after participating in a pharmacist-provided telephone medication therapy manage-
ment (PPMTM) program] and the control group in: 1) Medication/health-related 
problems (MHRPs); 2) Medication adherence; and 3) Total Part D drug costs. 
METHODS: This quasi-experimental study of Part D beneﬁ ciaries from a Texas health 
plan used the Andersen Model as its theoretical framework. Predisposing factors were 
age, gender, and race; need factors were number of medications, number of chronic 
diseases and medication regimen complexity. The intervention and control groups
were matched on number of medications and number of chronic diseases. The health 
behavior was PPMTM participation. Outcomes were changes in: 1) Number of 
MHRPs; 2) Medication adherence using medication possession ratio (MPR); and 3)
Total drug costs. Multivariate regression was used for group comparisons of outcomes.
RESULTS: The intervention (n  60) and control (n  60) groups were not statistically 
different in predisposing or need factors except for gender (intervention  51.7% male; 
control  28.3% male; p  0.009). At baseline, 4.8 (o2.7) MHRPs were identiﬁ ed in 
the intervention group and 9.2 (o2.9) in the control group. At the 6-month follow-up, 
2.5 (o2.0) and 7.9 (o3.0) MHRPs remained, respectively. Multivariate regression
revealed that the intervention group had signiﬁ cantly more MHRPs resolved (p 
0.0003) when compared to the control group, while controlling for predisposing and 
need factors. There were no other signiﬁ cant predictors of MHRP resolution, Analyses 
showed no signiﬁ cant predictors of change in MPR or total drug costs from baseline
to 6-month follow-up. CONCLUSIONS: A telephone MTM program was effective in
resolving MHRPs among Medicare beneﬁ ciaries; however, no signiﬁ cant differences 
existed between the intervention and control groups in medication adherence and total 
drug costs.
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OBJECTIVES: The initiation of Medicare Part D in 2006 offers an ideal opportunity
to study real-world decision-making and the role of adverse selection and other factors 
in insurance enrollment. Our objective was to identify predictors of Part D enroll-
ment among individuals with a range of health conditions and insurance designs. 
METHODS: The sample included all individuals in both the 2005 and 2006 Medical 
Expenditure Panel Survey (MEPS) datasets who were enrolled in Medicare, but not 
Medicaid, as of December 2005. A multivariate logistic regression was used to assess 
the effects of sociodemographics, health status, 2005 supplemental insurance cover-
age, and 2005 person-level out-of-pocket (OOP) drug expenditures on the likelihood 
of enrolling in Part D in 2006. MEPS sample weights were used to calculate standard 
errors. RESULTS: Out of 1,436 persons who met inclusion criteria, 657 (45.4%) 
enrolled in Part D during 2006. Compared to the no-Part D group, the Part D group 
was slightly older, had more non-whites, rural residents, and unmarried individuals,
and was slightly less educated and poorer. The Part D group had more beneﬁ ciaries
with Medigap coverage only (17.2% vs. 5.7%), fewer with employer-based coverage 
only (18.3% vs. 37.1%), and more with no private supplemental insurance (46.1% 
vs. 32.1%). In multivariate analyses, signiﬁ cant positive predictors of Part D enroll-
ment were having Medigap supplemental insurance only (OR: 1.99; 95% CI: 1.25–
3.19) and OOP drug expenditures q$2500 in 2005 (OR: 1.58; 95% CI: 1.03–2.41).
Most beneﬁ ciaries with employer-based coverage in 2005 maintained that coverage in
2006 (91.8%). CONCLUSIONS: Based on ﬁ rst-year data, fears of only the sickest
beneﬁ ciaries enrolling in Part D and employers withdrawing drug beneﬁ ts to retirees
seem to have been unwarranted. Existing coverage and high prior drug spending drove
the decision to enroll in Part D in what appears to have been a rational way.
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OBJECTIVES: The objectives were to describe angiotensin-converting enzyme inhibi-
tors (ACEI) and angiotensin II receptor blockers (ARB) use among Medicare Part D 
enrollees with diabetes and to identify patient characteristics that predict ACEI/ARB
utilization. METHODS: This is a longitudinal retrospective cohort study. The study 
sample included Medicare Part D enrollees from 6 states (Alabama, California, 
Florida, Mississippi, New York, and Ohio) aged 18 years or older with the diagnosis
of diabetes. Medicare Part D claims data for the ﬁ rst 6 months of 2006 were evaluated
for any utilization of ACEI/ARB. The outcome of interest was the percentage of at
least one claim for an ACEI or an ARB during the ﬁ rst half of 2006. RESULTS: A
total of 1,888,682 patients met our inclusion criteria. Mean age (oSD) was 71.6 
(o11.6) years, 59.5% were female, and 66.4% were white. Approximately 58.9%,
5.8%, 0.5% had coexisting hypertension, nephropathy, and hypertension  nephropa-
thy. Overall, 56.9% were receiving ACEI/ARB therapy. Logistic regression indicated 
that patients with coexisting hypertension  nephropathy and hypertension were 72%
and 36% more likely to use ACEI/ARB compared to patients without hypertension
and/or nephropathy. However, patients with nephropathy were 24% less likely to
receive ACEI/ARB therapy. Females, older patients, and patients of nonwhite races 
were also more likely to use ACEI/ARB. Patients with myocardial infarction, sleep 
apnea, coronary artery disease, retinopathy or heart failure were more likely to have 
used ACEI/ARB, while the opposite was true for those with hypercholesterolemia, 
peripheral vascular, cerebrovascular, or chronic obstructive pulmonary diseases. All 
results were statistically signiﬁ cant at P  .0001 level. CONCLUSIONS: Less than
60% of Medicare Part D enrollees with diabetes received ACEI/ARB therapy. Several
patient characteristics can predict ACEI/ARB use. Opportunities exist for quality-
improvement interventions that could increase the outcomes for high-risk patients.
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OBJECTIVES: Despite the huge cost of the program, the Centers for Medicare and 
Medicaid Services (CMS) maintains that cost-effectiveness is not considered in national 
coverage determinations (NCDs) for medical technologies. Our objective was to assess 
the cost-effectiveness of technologies and interventions that are the subject of Medicare 
NCDs in order to investigate whether an implicit cost-effectiveness threshold exists. 
In addition, we explored whether CMS have cited cost-effectiveness evidence in NCDs. 
METHODS: We reviewed NCD decision memos from 1999 through 2007 (n  103). 
A literature review was conducted for each coverage decision to ﬁ nd relevant economic
evaluations. The economic evaluation that best represented each coverage decision 
was included in a review of the cost-effectiveness of medical technologies considered 
in NCDs. RESULTS: Sixty-four coverage decisions were identiﬁ ed from 103 decision 
memos. Fifty were associated with a positive coverage decision and 14 with a 
